We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+10.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.08B
AUM Growth
+$170M
Cap. Flow
-$43.5M
Cap. Flow %
-1.41%
Top 10 Hldgs %
31.64%
Holding
198
New
2
Increased
42
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$41.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$21.9M
3
UTHR icon
United Therapeutics
UTHR
+$14.5M
4
TMO icon
Thermo Fisher Scientific
TMO
+$12.5M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.5M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$21.8M
2
STE icon
Steris
STE
+$20M
3
ILMN icon
Illumina
ILMN
+$18.6M
4
WAT icon
Waters Corp
WAT
+$17.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.67%
2 Real Estate 2.94%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
101
Sutro Biopharma
STRO
$411M
$7.44M 0.24%
40,015
-17,367
-30% -$3.4M
LTC
102
LTC Properties
LTC
$2.06B
$7M 0.23%
182,293
– –
QURE icon
103
uniQure
QURE
$2.93B
$6.96M 0.23%
225,921
+100,918
+81% +$3.38M
YMAB
104
DELISTED
Y-mAbs Therapeutics
YMAB
$6.69M 0.22%
197,820
– –
ZLAB icon
105
Zai Lab
ZLAB
$2.06B
$6.64M 0.22%
37,523
– –
ARVN icon
106
Arvinas
ARVN
$536M
$6.62M 0.22%
85,997
– –
SAGE
107
DELISTED
Sage Therapeutics
SAGE
$6.48M 0.21%
114,119
– –
FATE icon
108
Fate Therapeutics
FATE
$293M
$6.31M 0.21%
72,727
-77,616
-52% -$6.25M
ALGN icon
109
Align Technology
ALGN
$12.4B
$6.06M 0.2%
9,925
– –
TEVA icon
110
Teva Pharmaceuticals
TEVA
$41.2B
$6.02M 0.2%
607,651
-52,900
-8% -$560K
FOLD
111
DELISTED
Amicus Therapeutics
FOLD
$5.99M 0.19%
621,659
– –
RVTY icon
112
Revvity
RVTY
$12.7B
$5.73M 0.19%
37,094
– –
STE icon
113
Steris
STE
$22.5B
$5.71M 0.19%
27,655
-99,124
-78% -$20M
KURA icon
114
Kura Oncology
KURA
$826M
$5.7M 0.19%
273,463
– –
RETA
115
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.41M 0.18%
38,219
– –
AUPH icon
116
Aurinia Pharmaceuticals
AUPH
$1.93B
$5.16M 0.17%
397,920
– –
TRIL
117
DELISTED
Trillium Therapeutics Inc.
TRIL
$5.13M 0.17%
529,226
– –
DOC icon
118
Healthpeak Properties
DOC
$15.2B
$5.01M 0.16%
150,392
– –
VRNA
119
DELISTED
Verona Pharma
VRNA
$4.92M 0.16%
751,905
– –
CNC icon
120
Centene
CNC
$30.1B
$4.91M 0.16%
67,290
– –
ADUS icon
121
Addus HomeCare
ADUS
$2.18B
$4.73M 0.15%
54,237
+16,597
+44% +$1.61M
SNN icon
122
Smith & Nephew
SNN
$13.6B
$4.68M 0.15%
107,670
+8,110
+8% +$341K
PSNL icon
123
Personalis
PSNL
$1.31B
$4.55M 0.15%
179,731
– –
RCM
124
DELISTED
R1 RCM Inc. Common Stock
RCM
$4.5M 0.15%
202,351
+78,890
+64% +$1.9M
COGT icon
125
Cogent Biosciences
COGT
$7.07B
$4.36M 0.14%
537,742
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Tekla Capital Management held 198 positions worth $3.08B, up 5.9% from $2.91B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Tekla Capital Management's Q2 2021 filing shows 2 new, 42 increased, 41 reduced and 9 closed positions. Its largest new stake was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M. The largest sale was Elevance Health, an estimated $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2021 buy was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2021, an estimated $41.2M increase.
  • Tekla Capital Management's biggest Q2 2021 reduction was Elevance Health, cutting an estimated $21.8M.
  • Tekla Capital Management fully exited Morphic Holding, Inc. Common Stock in Q2 2021, selling an estimated $5.67M.
  • Tekla Capital Management's ten largest holdings make up 32% of its $3.08B portfolio in Q2 2021.
  • Tekla Capital Management opened 2 new positions and closed 9 in Q2 2021.
  • Tekla Capital Management's portfolio value rose 5.9% quarter-over-quarter to $3.08B.

Based on Tekla Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.